Patients must not currently be receiving any other investigational agents
Patients who are currently receiving other anticancer agents
Subject is currently being treated with other investigational agents.
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Currently receiving any investigational agents within the previous six weeks or received any tumor vaccines within the previous 6 weeks
Currently receiving any other investigational agents
EXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks
Currently receiving any other investigational agents
EXCLUSION CRITERIA FOR REGISTRATION: Currently receiving any other investigational agents or systemic cancer therapy
TREATMENT EXCLUSION: Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the study
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents or received any within the past 28 days
Patients who are currently receiving any other investigational agents.
Subjects who are currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving investigational agents that are intended as treatments of recurrent GBM.
Currently receiving any other investigational agents
Currently receiving any investigational agents
Currently receiving any other investigational agents
Currently receiving any investigational agents
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Currently receiving any other investigational agents
TREATMENT: Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks
Currently receiving any other investigational agents that are intended as treatments of the relapsed tumor
Currently receiving any other investigational agents
Patients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiation
Currently receiving any other investigational agents
Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Participants who are currently receiving any other investigational agents.
Currently receiving any other investigational agents, or exposure to any investigational drug or placebo within 4 weeks of study treatment
Currently receiving any other investigational agents
Currently receiving any other investigational agents.
Patients may not currently be receiving any other investigational agents for leukemia
Patients currently receiving other investigational agents
Currently receiving any investigational agents or have received any tumor vaccines within the previous six weeks
Currently receiving any other investigational agents
Receiving any investigational agents currently or within 30 days prior to study screening
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Currently receiving any other active investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving investigational agents
Currently receiving any other investigational agents that are intended as treatments of GBM
Patients who are currently receiving any other investigational agents.
Currently receiving any investigational agents or registration on another therapy based trial
Currently receiving any other investigational agents
Participants who are currently receiving any other investigational agents
Receiving any other investigational agents currently, or within time limits specified above prior to study day 1
Other investigational agents currently or within 30 days prior to study enrollment
Patients who are currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents that are intended as treatments of recurrent GBM
Patients currently receiving other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients currently receiving any other investigational agents;
Currently receiving investigational agents in a clinical trial
Currently receiving investigational agents in a clinical trial
Participants who are currently receiving any other investigational agents or have received investigational agents within the past 3 months will be excluded
Patients may not be currently receiving any other investigational agents within 4 weeks of study registration
Patients must not currently be using other investigational agents
